"Piperidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of hexahydropyridines.
| Descriptor ID |
D010880
|
| MeSH Number(s) |
D03.383.621
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperidines".
Below are MeSH descriptors whose meaning is more specific than "Piperidines".
This graph shows the total number of publications written about "Piperidines" by people in this website by year, and whether "Piperidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 3 | 0 | 3 |
| 2000 | 2 | 1 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 1 | 3 |
| 2004 | 2 | 2 | 4 |
| 2005 | 2 | 1 | 3 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 6 | 7 |
| 2008 | 1 | 2 | 3 |
| 2009 | 0 | 4 | 4 |
| 2010 | 3 | 1 | 4 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 3 | 1 | 4 |
| 2014 | 3 | 1 | 4 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 3 | 4 |
| 2017 | 3 | 2 | 5 |
| 2018 | 6 | 4 | 10 |
| 2019 | 5 | 5 | 10 |
| 2020 | 4 | 4 | 8 |
| 2021 | 6 | 5 | 11 |
| 2022 | 2 | 2 | 4 |
| 2023 | 1 | 2 | 3 |
| 2024 | 2 | 2 | 4 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Piperidines" by people in Profiles.
-
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review. Target Oncol. 2025 Mar; 20(2):217-234.
-
Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk. JAMA Netw Open. 2024 Nov 04; 7(11):e2446336.
-
Regulatory roles of NAMPT and NAD+ metabolism in uterine leiomyoma progression: Implications for ECM accumulation, stemness, and microenvironment. Redox Biol. 2024 12; 78:103411.
-
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Ann Rheum Dis. 2024 Oct 21; 83(11):1561-1571.
-
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024 04 18; 143(16):1616-1627.
-
Pathophysiological Sex Differences in Heart Failure Progression After Acute Coronary Syndrome: Insights From the EXAMINE Trial. J Card Fail. 2024 Jun; 30(6):767-777.
-
Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity. Molecules. 2023 Sep 15; 28(18).
-
Treatment of Chronic Inflammatory Pouch Conditions With Tofacitinib: A Case Series From 2 Tertiary IBD Centers in the United States. Inflamm Bowel Dis. 2023 09 01; 29(9):1504-1507.
-
Looking from the Past to the Future: How Janus Kinase Inhibitors Have Altered the Therapy of Ulcerative Colitis. Dig Dis Sci. 2023 06; 68(6):2248-2251.
-
Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes. Dig Dis Sci. 2023 04; 68(4):1464-1472.